This review highlights A. tatarinowii and its bioactive components as innovative candidates for CVD management. The incorporation of nanotechnology represents a transformative strategy to optimize their pharmacological effects. Future research should focus on clinical validation and further mechanistic studies to facilitate their translation into modern cardiovascular medicine.